BRAF and thyroid gland carcinoma: Intrinsic resistance to vemurafenib in BRAF-mutant thyroid cancer cell lines has been shown to be due to attenuation of the negative feedback by vemurafenib on the NRG1-HER3/HER2 pathway, with the consequent reactivation of ERK [2].